NeuroSense Therapeutics 株価情報 (NASDAQ: NRSN)

最新ニュース NeuroSense Therapeutics (NASDAQ:NRSN) 株価情報

NeuroSense Therapeutics

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics Ltd

Mizuho analyst Nitin Kumar maintains ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) with a Outperform and lowers the price target from $127 to $125.

News

Price Target

Analyst Ratings

Mizuho Maintains Outperform on ConocoPhillips, Lowers Price Target to $125

Bitcoin price fell by 1.63% on Tuesday to $102,577.22 after a rise of 9.06% in the last week, <a href="https://www.benzinga.com/money/how-to-buy-bitcoin-btc-best-bonuses-august-2024">and over 21.96% in the past month</a>. As Bitcoin maintains the $2 trillion market cap, giants like Metaplanet, BlackRock, and Goldman Sachs are scaling their BTC holdings despite short-term volatility signals.&nbsp;
First-time buyer wallets that are engaging with BTC are showing great strength, and their First-Time Buyers RSI (Relative Strength Index) has remained at 100 throughout the week. This metric implies a consistent retail interest, which may be driven by fear of missing out (FOMO). The FOMO based buying is accompanied with rapid price growth of a coin.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto? <a href="http://coinbase-consumer.sjv.io/m5ALXy">Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade</a> on Coinbase.</li>
</ul>
But unlike new investors, seasoned investors are not adding fresh capital as much. Momentum buyers, who typically benefit from sustained price trends, are showing relatively low activity levels. Glassnode noted that there was a 30-day RSI of only 11 from these buyers. Meanwhile, profit-taking activity is rising, which indicates there may be a consolidation phase if new inflows slow down.
However, there is great market activity in the form of institutional accumulation.
Japan-based Metaplanet, having recently bought 1,241 BTC, is doubling down on its Bitcoin strategy. The firm announced that it&#8217;s issuing $15 million in 0% interest bonds to accelerate BTC accumulation. On full subscription, the proceeds would add 147 BTC at current prices, bringing Metaplanet further towards its 10,000 BTC target by the end of 2025. With 6,796 BTC already held, Metaplanet is emerging as a major institutional buyer outside North America.
Meanwhile, corporate giants remain in the top slot of Bitcoin holdings in 2025. MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), rebranded as &#8220;Strategy,&#8221; just revealed a massive purchase of 13,390 BTC amounting to $1.34 billion, taking its total holdings to 568,840 BTC.&nbsp;
At an average cost basis of $69,287 per coin, Strategy&#8217;s accumulation plan is aggressive but risk-ridden. Critics, like economist Peter Schiff, warn Strategy that in case Bitcoin&#8217;s price goes down, it may even go below their coins&#8217; average purchase price. Hence, Strategy could get into trouble as the company had borrowed money to fund the acquisitions.
But the institutional capital flows show no sign of slowing. BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) has purchased Bitcoin for 20 straight days, and added 686 BTC worth approximately $70 million in the most recent purchase. Its holdings in the IBIT spot Bitcoin ETF have risen to 621,600 BTC.
Goldman Sachs Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)has also increased its ownership in BlackRock&#8217;s ETF by 28%. It puts Goldman in control of more than half of all U.S. spot Bitcoin ETF holdings. With this growth rate, BlackRock and Goldman could collectively be in control of 5% of the overall supply of Bitcoin by 2026.
Despite short-term volatility, there's optimism for BTC in the market. If new money continues to pour in, and Bitcoin's price point at $100,000 can hold, BTC could be in for a pleasant growth.
More Opportunities:
<ul class="wp-block-list">
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

MSTR

Bitcoin Price Slips to $102,577 Amid Growing Institutional Interest

Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy and lowers the price target from $68 to $66.

ARCT

Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $66

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates enCore Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EU#NASDAQ">EU</a>) with a Buy and maintains $2.75 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on enCore Energy, Maintains $2.75 Price Target

Mizuho analyst William Janela maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Underperform and lowers the price target from $20 to $19.

Mizuho Maintains Underperform on APA, Lowers Price Target to $19

CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) reported <a href="https://www.benzinga.com/pressreleases/25/05/b45371204/cyberark-announces-strong-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">fiscal first-quarter</a> results on Tuesday. Quarterly revenue increased 43% year over year to $317.60 million, beating the analyst consensus estimate of $305.23 million. 
The cybersecurity company posted an adjusted EPS of&nbsp;$0.98, which beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of&nbsp;$0.79.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43810016/cyberark-stock-poised-to-surge-over-20-as-bofa-raises-price-target-metrics-show-continued-execution-on-all-fronts" rel="noreferrer noopener">CyberArk Stock Poised To Surge Nearly 22%, Says BofA: &#8216;Metrics Show Continued Execution On All Fronts&#8217;</a>
The stock price fell after the report.
Segments: Revenues from Subscriptions expanded 60% year over year (Y/Y) to $250.6 million. Maintenance and professional services were $67.0 million versus $65.3 million Y/Y.
Key Performance Indicators:&nbsp;Annual Recurring Revenue (ARR) increased&nbsp;50% Y/Y&nbsp;to&nbsp;$1.22 billion. The subscription portion of ARR was&nbsp;$1.03 billion, implying a&nbsp;65% Y/Y&nbsp;growth.&nbsp;
The Maintenance portion of ARR was&nbsp;$188 million, down by 1.1% Y/Y. Recurring revenue grew&nbsp;45%&nbsp;Y/Y to&nbsp;$298.2 million.&nbsp;
CyberArk held&nbsp;$776.1 million&nbsp;in cash and equivalents as of March 31, 2025.
Outlook: CyberArk expects fiscal second-quarter revenue of $312.0 million—$318.0 million, versus the <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">analyst consensus estimate</a> of $305.23 million.
It projected an adjusted EPS of&nbsp;$0.74-$0.81&nbsp;versus the&nbsp;analyst consensus estimate of&nbsp;$0.79.
CyberArk expects fiscal 2025 revenue of $1.313 billion—$1.323 billion (<a href="https://www.benzinga.com/25/02/43698118/cyberark-q4-earnings-revenue-surges-41-subscription-growth-and-strong-arr-projects-continued-growth-in-identity-security-market" target="_blank" rel="noopener">prior $1.308 billion—$1.318 </a><a href="https://www.benzinga.com/25/02/43698118/cyberark-q4-earnings-revenue-surges-41-subscription-growth-and-strong-arr-projects-continued-growth-in-identity-security-market" target="_blank" rel="noreferrer noopener">billion</a>) versus the analyst consensus estimate of $1.320 billion. The company expects an adjusted EPS outlook of $3.73-$3.85 (prior $3.55-$3.70) versus the analyst consensus estimate of $3.66.
It reiterated an ARR of $1.410 billion—$1.420 billion as of December 31, 2025, up 21%.
Price Action:&nbsp;CYBR stock is down&nbsp;3.44%&nbsp;at&nbsp;$355.01 premarket at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45357365/salesforce-sales-cloud-ai-integration-and-cloud-upsells-drive-analyst-confidence-in-long-term-growth" target="_blank" rel="noreferrer noopener">Salesforce Sales Cloud, AI Integration, And Cloud Upsells Drive Analyst Confidence In Long-Term Growth</a></li>
</ul>
Photo: Shutterstock

Earnings

Guidance

CYBR

CyberArk Stock Slips Despite Strong Q1 Growth In Subscriptions And Raised 2025 Outlook

Canaccord Genuity analyst Joseph Vafi maintains Advantage Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) with a Buy and lowers the price target from $3.5 to $2.5.

Canaccord Genuity Maintains Buy on Advantage Solutions, Lowers Price Target to $2.5

Mizuho analyst William Janela downgrades Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) from Outperform to Neutral and lowers the price target from $32 to $31.

Downgrades

Mizuho Downgrades Murphy Oil to Neutral, Lowers Price Target to $31

Despite a rocky year-to-date drop of over 16%, Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rallied 40% from its April lows and catapulted back to <a href="https://www.benzinga.com/markets/equities/25/02/43962728/tesla-loses-1-trillion-valuation-as-shares-plunge-8-elon-musks-doge-role-brand-backlash-fuel-sell-off">the $1 trillion club</a>. 
The electric vehicle maker, which lost its $1 trillion valuation in February, has powered up more than 26% in the past month thanks to a robotaxi update, technical momentum, and a sudden reprieve in <a href="https://www.benzinga.com/government/regulations/25/05/45367206/sp-500-rallies-over-3-on-us-china-90-day-tariff-truce-but-experts-warn-it-doesnt-guarantee-a-complete-resolution-of-the-trade-war">U.S.-China trade tensions</a>.
With shares now trading at $318.38, the Tesla stock chart now reads like a technician's dream. See below.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045647/Screenshot-2025-05-13-at-2.14.39-PM.png" alt="" class="wp-image-913139" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045647/Screenshot-2025-05-13-at-2.14.39-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13045647/Screenshot-2025-05-13-at-2.14.39-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0513">Chart created using Benzinga Pro</a>
Read Also: <a href="https://www.benzinga.com/markets/equities/25/05/45366272/republicans-target-ev-perks-with-new-bill-ford-tesla-rivian-face-fallout-as-200-billion-in-battery-belt-investments-hang-in-balance">Republicans Target EV Perks With New Bill: Ford, Tesla, Rivian Face Fallout As $200 Billion In Battery Belt Investments Hang In Balance</a>
<h2 class="wp-block-heading">TSLA: Chart Whisperers Go Bullish</h2>
Tesla stock has closed above the closely watched 200-day simple moving average (currently at $294.06) and is trading comfortably above its five, 20 and 50-day exponential moving averages — a classic hallmark of a strong bullish trend.
The eight-day and 20-day simple moving averages are both giving firm buy signals, with prices well above those levels. Meanwhile, the Moving Average Convergence Divergence (MACD) indicator prints a healthy 11.17 and the Relative Strength Index (RSI) sits at 64.77 — suggesting momentum without overheating.
To top it off, Tesla just confirmed a triple bottom formation, a technical pattern, repeatedly bouncing off the support at around $225. This technical chart pattern often precedes sustained bullish reversals. Charts indicate a clear bullish uptrend from here, with key support zones at $289 and $225.
<h2 class="wp-block-heading">Robotaxi Dreams Vs. China Blues</h2>
While Wall Street is fixated on Musk's promised robotaxi debut in Austin next month — albeit with "maybe 10–20 vehicles" — China remains Tesla's Achilles' heel. The company slid to <a href="https://cnevpost.com/2025/05/12/automakers-share-china-nev-market-apr-2025/">eighth</a> place in China's new energy vehicle market in April, capturing just 3.2% share, down sharply from 7.5% in March.
BYD Co Ltd (OTCPK:BYDDF) (OTCPK:BYDDY) continues to dominate the Chinese NEV space, posting a staggering 268,778 units sold in April. Tesla's local deliveries dropped nearly 9% year-over-year. And yet, none of this has derailed the current rally.
<h2 class="wp-block-heading">Back In The Trillionaire Club</h2>
Thanks to a nearly 7% pop on Monday, Tesla rejoined the $1 trillion market cap club. Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are also members.
The bigger surprise is just how fast sentiment flipped. CEO Elon Musk's decision to dial down his political involvement and refocus on Tesla may have rekindled investor faith. Although David Sacks, the White House&#8217;s &#8220;crypto czar,&#8221; recently <a href="https://www.benzinga.com/markets/25/04/45094266/elon-musk-isnt-completely-out-of-doge-hes-just-in-maintenance-mode-says-david-sacks-if-he-doesnt-theres-gonna-be-a-huge-backsliding" target="_blank" rel="noreferrer noopener">stated </a>that Musk was not completely out of DOGE.
If momentum holds and robotaxi execution doesn&#8217;t stumble, Tesla may be turbocharged for the second half of the year.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45372179/us-china-tariff-truce-adds-nearly-45-billion-to-net-worth-of-elon-musk-jeff-bezos-mark-zuckerberg">Elon Musk, Jeff Bezos, Mark Zuckerberg Gain Billions As US-China Tariff Truce Boosts Tech Billionaires&#8217; Fortunes</a></li>
</ul>
Image: Shutterstock

Technicals

Tech

Trading Ideas

AAPL

AMZN

BYDDF

BYDDY

NVDA

TSLA

Tesla Back In The Trillionaire Club: EV Stock Revs Back With 40% Rebound, Robotaxi Update

Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.68) by 44.12 percent. This is a 25.49 percent increase over losses of $(0.51) per share from the same period last year.

Earnings Beats

MNPR

Monopar Therapeutics Q1 EPS $(0.38) Beats $(0.68) Estimate

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) from Neutral to Neutral.

GRYP

HC Wainwright & Co. Reiterates Neutral on Gryphon Digital Miningto Neutral

Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.20) by 120 percent. This is a 25.71 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $257.88 thousand which missed the analyst consensus estimate of $2.63 million by 90.21 percent. This is a 103.32 percent increase over sales of $126.84 thousand the same period last year.

Earnings Misses

COYA

Coya Therapeutics Q1 EPS $(0.44) Misses $(0.20) Estimate, Sales $257.88K Miss $2.63M Estimate

MeiraGTx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGTX#NASDAQ">MGTX</a>) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.45) by 13.33 percent. This is a 59.38 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $1.93 million which missed the analyst consensus estimate of $4.43 million by 56.56 percent. This is a 176.33 percent increase over sales of $697.00 thousand the same period last year.

MGTX

MeiraGTx Hldgs Q1 EPS $(0.51) Misses $(0.45) Estimate, Sales $1.93M Miss $4.43M Estimate

Ripple&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) price has gained upward momentum, touching $2.43 on Tuesday and marking <a href="https://www.benzinga.com/money/how-to-buy-ripple-xrp">an impressive 395% increase over the past year</a>. A prominent crypto analyst, Edo Farina, who is known for his XRP support on X, released a video analysis wherein he projected that XRP could surge to $10 or higher in 2025.
The optimistic outlook is supported by several factors, including recent legal victories and evolving market dynamics.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto? <a href="http://coinbase-consumer.sjv.io/m5ALXy">Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade</a> on Coinbase.</li>
</ul>
One of the main reasons Farina highlighted is Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) Dominance. While relatively high, he points to historical trends where a drop in Bitcoin&#8217;s market share from around 40% to 30% has historically signaled the beginning of an &#8220;altcoin season.&#8221;
He suggests such a shift could serve as a powerful catalyst for a broader altcoin market breakout, which can further push XRP toward a 4X rally from its current levels. It could help the token hit the notable $10 mark.&nbsp;
"If $XRP hits $10, you can bet it'll hit $100," Farina tweeted. Adding to this positive market sentiment, the XRP/BTC trading pair has moved upward and surged by more than 7% in the past week. This short-term price increase is particularly noteworthy as it occurs within a potentially bullish technical formation.
On the XRP/BTC chart, a falling wedge pattern has emerged. This pattern, which is characterized by converging lower highs and lower lows, often signals a weakening of selling pressure and the possibility of a strong upward breakout.
Technical indicators are also showing signs of bullish resurgence, with the Relative Strength Index (RSI) climbing to 62 and the Moving Average Convergence Divergence (MACD) indicating a bullish crossover.
A factor supporting the positive outlook is the recent resolution of the legal case between Ripple and the U.S. Securities and Exchange Commission (SEC). With XRP no longer classified as a security in the U.S., Ripple has gained the regulatory green light to offer the token to financial institutions.
The development is expected to boost investor confidence, and pave the way for wider global adoption of XRP.
"Global travel giant TRAVALA accepts $XRP as a payment method! Mass adoption is coming!" Farina highlighted.&nbsp;
However, experts say that Ripple needs to aggressively push for the successful integration of XRP into the global financial infrastructure, especially when it comes to cross-border payments and the tokenization of Real World Assets (RWAs).&nbsp;
There are several other catalysts behind this growth of XRP. It is mentioned as a possible component of the US strategic reserve. Besides, Amber, a company listed on Nasdaq, recently announced its intention to include XRP in its $100 million crypto ecosystem reserve, alongside other major cryptocurrencies like BNB, Solana, Bitcoin, and Ethereum.&nbsp;
Considering all these factors, the current market conditions seem favorable for XRP to make a bull run.
More Opportunities:
<ul class="wp-block-list">
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

$BTC

$XRP

XRP Price Surges Amid Bullish Technical Indicators, Sees More Institutional Adoption

Needham analyst John Todaro reiterates CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) with a Buy and maintains $15 price target.

CMPO

Needham Reiterates Buy on CompoSecure, Maintains $15 Price Target

Wall Street opened Tuesday with cautious gains after inflation data for April came in cooler than expected, calming investor concerns over <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45374267/inflation-eases-in-april-as-trumps-tariffs-dont-push-prices-higher">tariff-driven price spikes. </a>
April's inflation report showed consumer prices rising 2.3% year over year, slightly below the 2.4% forecast and down from the previous month's reading of 2.4%. On a monthly basis, prices increased 0.2%, rebounding from March's 0.1% decline but missing expectations of a 0.3% gain.
Core inflation, which excludes food and energy, held steady at 2.8% annually—matching both March&#8217;s figure and economists' forecasts. Month over month, core prices rose 0.2%, a modest acceleration from March's 0.1% increase but still softer than the expected 0.3%.
Shelter remained a major contributor to inflation, rising 0.3% in April and accounting for over half of the monthly increase in the overall Consumer Price Index. Meanwhile, several categories posted price declines, including airline fares, used cars and trucks, communication services and apparel.
Despite inflation coming in below forecasts, expectations for interest rate cuts held steady. Traders still see just an 8% chance of a cut in June, rising to 38% for July. Markets continue to price in a total of 60 basis points in rate reductions by year-end, well below the almost 75 basis points priced a week ago.
The Nasdaq 100 led major benchmarks, rising 0.37% and on track to open at its highest level in 10 weeks.
<h3 class="wp-block-heading">Index Moves: Nasdaq Shakes Off Bear Market</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Index</th>
<th>Level</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>S&amp;P 500</td>
<td>5852.58</td>
<td>+0.14%</td>
</tr>
<tr>
<td>Dow Jones Industrial Average</td>
<td>42268</td>
<td>-0.33%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20945</td>
<td>+0.37%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 9:15 a.m. ET</figcaption></figure>
Since its April low, the tech-heavy benchmark – as tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) – has rallied 27%, sharply rebounding from last month's bear market triggered by the implementation of Trump's new tariffs on April 2.
Semiconductors remained the strongest segment within tech. The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) added another 0.7% in premarket after an explosive 7.2% surge Monday, buoyed by investor optimism following the U.S.-China trade truce.
<h3 class="wp-block-heading">Top Post-CPI Movers: Financials Lead</h3>
Shares of credit and fintech firms jumped in the 30 minutes following the inflation report:
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>Change (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>)</td>
<td>+2.42%</td>
</tr>
<tr>
<td>American Express Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>)</td>
<td>+2.33%</td>
</tr>
<tr>
<td>NetEase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>)</td>
<td>+1.97%</td>
</tr>
<tr>
<td>KLA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>)</td>
<td>+1.85%</td>
</tr>
<tr>
<td>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>)</td>
<td>+1.44%</td>
</tr>
<tr>
<td>Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>)</td>
<td>+1.31%</td>
</tr>
<tr>
<td>Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)</td>
<td>+1.12%</td>
</tr>
<tr>
<td>Lowe's Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>)</td>
<td>+1.09%</td>
</tr>
<tr>
<td>ServiceNow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>)</td>
<td>+0.96%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500 Premarket Gainers</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>Change (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>)</td>
<td>+9.73%</td>
</tr>
<tr>
<td>Live Nation Entertainment Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>)</td>
<td>+3.53%</td>
</tr>
<tr>
<td>Air Products and Chemicals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>)</td>
<td>+3.42%</td>
</tr>
<tr>
<td>Western Digital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</td>
<td>+2.92%</td>
</tr>
<tr>
<td>Builders FirstSource Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>)</td>
<td>+2.31%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500 Premarket Losers</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>Change (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-9.78%</td>
</tr>
<tr>
<td>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>-5.11%</td>
</tr>
<tr>
<td>Texas Pacific Land Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>)</td>
<td>-4.05%</td>
</tr>
<tr>
<td>Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>)</td>
<td>-3.78%</td>
</tr>
<tr>
<td>PPG Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>)</td>
<td>-3.51%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance">UnitedHealth Names New CEO, Suspends 2025 Guidance, Stock Plunges </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

ETFs

BLDR

COIN

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

ENPH

FSLR

KLAC

NTES

SHOP

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Wall Street Climbs As Inflation Cools, Nasdaq 100 Hits 10-Week Highs

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $5 price target.

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $5 Price Target

<ul>
<li>There is a critical need for trustworthy, hyper-personalized information earlier in the diagnosis and treatment journey to empower patients to participate in their care</li>
<li>The partnership will initially focus on endometriosis and hematology; high-need therapeutic areas where patients are actively seeking information</li>
<li>Connecting tailored information with relevant, motivated audiences will reinvent the way DTC advertising interacts and engages with consumers</li>
</ul>
NEW YORK, May 13, 2025 /PRNewswire/ --&nbsp;<a href="https://ubiehealth.com/company">Ubie</a>, an AI-driven and medically vetted healthcare prediction platform that guides patients to the care they need, and <a href="https://cmimediagroup.com/">CMI Media Group</a>, a WPP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPP#NYSE">WPP</a>), healthcare media agency, announced a partnership aiming to transform direct-to-consumer (DTC) advertising, beginning with women's health and hematology/oncology. The collaboration integrates Ubie's AI Symptom Checker with CMI's precision media expertise to address the pharmaceutical industry's challenges in reaching patients with personalized, engaging messaging at scale. This combination will help accelerate time to diagnosis and the identification of the best available treatment.

Ubie And CMI Media Group Partner To Transform Direct-To-Consumer Advertising, Beginning With Women's Health And Hematology/Oncology

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares are trading lower <a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener">on Tuesday</a>. The firm revealed that its advanced steer-by-wire system, featured in the ET9 executive sedan, has secured a key regulatory approval in Europe, <a href="https://cnevpost.com/2025/05/13/nio-gets-european-certification-steer-by-wire-et9/" target="_blank" rel="noreferrer noopener">reports</a> CnEV Post, citing a statement from CEO William Li on Weibo.
This development positions the electric vehicle manufacturer as a global frontrunner in deploying next-generation driving technologies.
The SBW technology on the ET9 has received the E-Mark certification under the United Nations Economic Commission for Europe framework, following assessment by the Spanish automotive certification group Applus IDIADA.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45357613" rel="noreferrer noopener">China Tariff De-Escalation Biggest Winners Include Tesla, Apple: &#8216;New Tech Highs Back On The Table Now For 2025&#8217;</a>
This marks the first time the organization has endorsed an SBW-enabled vehicle in the region.
NIO launched the ET9, its most premium offering to date, during Nio Day 2024.
Priced at RMB 788,000 (approximately $109,560), the four-seater sedan began reaching customers in China at the end of March, CnEV Post adds. The company delivered 810 units in April, its first full delivery month, according to CnEVPost data.
Alongside the ET9 milestone, NIO is refreshing several key models in its lineup.
Beginning May 10, customers in China can place pre-orders for updated versions of the ES6 SUV, EC6 coupe SUV, and the ET5 and ET5 Touring sedans. Showrooms will simultaneously unveil <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45322004/whats-going-on-with-nio-stock-today-23" rel="noreferrer noopener">the revamped ES6 and EC6 models.</a>
NIO recorded 23,900 vehicle deliveries in April, <a target="_blank" href="https://www.benzinga.com/25/05/45134925/chinese-ev-companies-see-huge-april-growth-xpeng-surges-273-in-deliveries" rel="noreferrer noopener">a 53% year-over-year increase.</a>
The surge in shipments indicates strong demand, even as the company invests in innovative features like SBW and explores international market opportunities.
Price Action: NIO shares are trading lower by 2.02% to $4.115 at last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45354683" target="_blank" rel="noreferrer noopener">Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black</a></li>
</ul>
Photo by Tada Images via Shutterstock

Eurozone

Markets

Movers

Media

General

What's Going On With NIO Stock On Tuesday?

New partnership offers Omega's operator partners exclusive benefits; Omega takes equity stake in Sunbound.
WASHINGTON, May 13, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4426049-1&amp;h=738334504&amp;u=https%3A%2F%2Fwww.sunboundhomes.com%2F&amp;a=Sunbound">Sunbound</a>, a leader in finance and accounts receivable solutions for senior living operators, today announced a strategic partnership with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4426049-1&amp;h=737281245&amp;u=https%3A%2F%2Fwww.omegahealthcare.com%2F&amp;a=Omega+Healthcare+Investors">Omega Healthcare Investors</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>), one of the nation's premier real estate investment trusts (REITs) that provides financing and capital solutions to Skilled Nursing Facility (SNF) and Assisted Living Facility (ALF) operators across the U.S. and the U.K. Through this agreement, Omega's extensive network of operator partners will receive preferred access and pricing to Sunbound's industry-leading payments, accounts receivable and financing solutions.

Sunbound Announces Strategic Partnership with Omega Healthcare Investors To Enhance Financing Solutions

Small Cap

Press Releases

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics is on Verge of Potential Blockbuster Pharma Deal as ALS Drug Shows 58% Survival Improvement

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

Comments

NeuroSense Therapeutics

ニュース

最新ニュース NeuroSense Therapeutics (NASDAQ:NRSN) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル